Novonesis AS 

€51.26
201
-€0.36-0.7% Thursday 19:45

Statistics

Day High
50.8
Day Low
50.6
52W High
65.02
52W Low
44.99
Volume
100
Avg. Volume
-
Mkt Cap
0
P/E Ratio
42.3
Dividend Yield
1.7%
Dividend
0.87

Upcoming

Dividends

1.7%Dividend Yield
Mar 26
€0.57
Aug 25
€0.3
Apr 25
€0.56
Sep 24
€0.27
May 24
€0.27
10Y Growth
3.45%
5Y Growth
4.27%
3Y Growth
-14.01%
1Y Growth
0.7%

Earnings

5MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
2.73
4.39
6.05
7.71
Expected EPS
5.749242847795963
Actual EPS
N/A

Financials

7.98%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
3.83BRevenue
305.8MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NZM2.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global pharmaceutical company that competes with Novonesis AS in the development and marketing of medications and vaccines for various diseases, including those in areas where Novonesis may operate.
Merck
MRK
Mkt Cap214.76B
Merck & Co., Inc. is a leading healthcare company that develops innovative pharmaceuticals and vaccines, directly competing with Novonesis AS in several therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is a diversified healthcare giant that competes with Novonesis AS through its pharmaceutical division, developing drugs that may overlap with Novonesis' product portfolio.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline is a global healthcare company that competes with Novonesis AS in the pharmaceutical and healthcare market, particularly in the development of vaccines and medications.
Novartis
NVS
Mkt Cap237.61B
Novartis is a multinational pharmaceutical company that competes with Novonesis AS in researching, developing, manufacturing, and marketing a wide range of healthcare products.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie is a biopharmaceutical company that competes with Novonesis AS in the discovery, development, and commercialization of new medicines and therapies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Novonesis AS in the development of prescription pharmaceuticals in several therapeutic areas.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is a healthcare company that competes with Novonesis AS in the pharmaceutical and diagnostics industries, focusing on oncology, immunology, and infectious diseases.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is a global healthcare leader that competes with Novonesis AS in the development and marketing of therapeutic solutions in areas such as rare diseases, multiple sclerosis, and oncology.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca is a global, science-led biopharmaceutical business that competes with Novonesis AS in the discovery, development, and commercialization of prescription medicines, particularly in the oncology sector.

About

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Show more...
CEO
Ms. Ester Baiget
Employees
10582
Country
DK
ISIN
DK0060336014
WKN
000A1JP9Y

Listings

0 Comments

Share your thoughts

FAQ

What is Novonesis AS stock price today?
The current price of NZM2.F is €51.26 EUR — it has decreased by -0.7% in the past 24 hours. Watch Novonesis AS stock price performance more closely on the chart.
What is Novonesis AS stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Novonesis AS stocks are traded under the ticker NZM2.F.
Is Novonesis AS stock price growing?
NZM2.F stock has risen by +3.1% compared to the previous week, the month change is a +3.81% rise, over the last year Novonesis AS has showed a -6.56% decrease.
When is the next Novonesis AS earnings date?
Novonesis AS is going to release the next earnings report on May 05, 2026.
What were Novonesis AS earnings last quarter?
NZM2.F earnings for the last quarter are 0.45 EUR per share, whereas the estimation was 0.67 EUR resulting in a -33.16% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Novonesis AS revenue for the last year?
Novonesis AS revenue for the last year amounts to 3.83B EUR.
What is Novonesis AS net income for the last year?
NZM2.F net income for the last year is 305.8M EUR.
Does Novonesis AS pay dividends?
Yes, NZM2.F dividends are paid semi-annual. The last dividend per share was 0.57 EUR. As of today, Dividend Yield (FWD)% is 1.7%.
How many employees does Novonesis AS have?
As of April 03, 2026, the company has 10,582 employees.
In which sector is Novonesis AS located?
Novonesis AS operates in the Materials sector.
When did Novonesis AS complete a stock split?
The last stock split for Novonesis AS was on November 28, 2011 with a ratio of 5:1.
Where is Novonesis AS headquartered?
Novonesis AS is headquartered in Lyngby, DK.